Halozyme Therapeutics Management
Management criteria checks 2/4
Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 10.25 years. total yearly compensation is $11.82M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $25.59M. The average tenure of the management team and the board of directors is 2.2 years and 10.3 years respectively.
Key information
Helen Torley
Chief executive officer
US$11.8m
Total compensation
| CEO salary percentage | 7.8% |
| CEO tenure | 10.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.2yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today
Sep 08Halozyme Therapeutics raises $625M through convertible senior notes due 2028
Aug 16Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off
Aug 03Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jul 26Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Jun 10Halozyme: Antares Pharma Bolsters Growth Prospects
May 19Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Apr 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$12m | US$920k | US$282m |
| Sep 30 2023 | n/a | n/a | US$254m |
| Jun 30 2023 | n/a | n/a | US$234m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$10m | US$872k | US$202m |
| Sep 30 2022 | n/a | n/a | US$211m |
| Jun 30 2022 | n/a | n/a | US$366m |
| Mar 31 2022 | n/a | n/a | US$435m |
| Dec 31 2021 | US$7m | US$830k | US$403m |
| Sep 30 2021 | n/a | n/a | US$409m |
| Jun 30 2021 | n/a | n/a | US$229m |
| Mar 31 2021 | n/a | n/a | US$163m |
| Dec 31 2020 | US$7m | US$791k | US$129m |
| Sep 30 2020 | n/a | n/a | US$22m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$6m | US$761k | -US$72m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$43m |
| Mar 31 2019 | n/a | n/a | -US$51m |
| Dec 31 2018 | US$6m | US$725k | -US$80m |
| Sep 30 2018 | n/a | n/a | US$46m |
| Jun 30 2018 | n/a | n/a | US$76m |
| Mar 31 2018 | n/a | n/a | US$68m |
| Dec 31 2017 | US$5m | US$671k | US$63m |
Compensation vs Market: Helen's total compensation ($USD11.82M) is above average for companies of similar size in the US market ($USD8.45M).
Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.
CEO
Helen Torley (60 yo)
10.3yrs
Tenure
US$11,820,858
Compensation
Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.3yrs | US$11.82m | 0.53% $ 25.6m | |
| Senior VP & CFO | 2.2yrs | US$3.85m | 0.012% $ 585.3k | |
| Senior VP & Chief Technical Officer | no data | US$3.24m | 0.13% $ 6.4m | |
| Senior VP & Chief Legal Officer | 2.3yrs | US$3.61m | 0.0092% $ 441.6k | |
| Chief Operations Officer | less than a year | no data | no data | |
| Head of Investor Relations & Corporate Communications | 2.3yrs | no data | no data | |
| Senior Vice President of Human Resources | 4.3yrs | no data | no data | |
| Head of Quality | no data | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
2.2yrs
Average Tenure
59yo
Average Age
Experienced Management: HALO's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.3yrs | US$11.82m | 0.53% $ 25.6m | |
| Independent Director | 17.8yrs | US$460.02k | 0.14% $ 6.8m | |
| Independent Chair of the Board | 8.7yrs | US$555.02k | 0.031% $ 1.5m | |
| Member of the Scientific Advisory Board | 19.7yrs | no data | no data | |
| Member of the Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 10.3yrs | US$68.17k | no data | |
| Member of Scientific Advisory Board | 19.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 18.8yrs | no data | no data | |
| Independent Director | 11.1yrs | US$471.83k | 0.078% $ 3.7m | |
| Independent Director | 9.3yrs | US$458.48k | 0.046% $ 2.2m | |
| Independent Director | 5.6yrs | US$470.02k | 0.020% $ 984.1k | |
| Independent Director | 2.1yrs | US$455.02k | 0.0049% $ 234.5k |
10.3yrs
Average Tenure
66yo
Average Age
Experienced Board: HALO's board of directors are seasoned and experienced ( 10.3 years average tenure).